NSCLC, FDA and Tagrisso
AstraZeneca’s Tagrisso gains FDA approval for stage III NSCLC
Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.
AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLC
AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Tagrisso (osimertinib) for expanded use in lung cancer. The regulatory body has approved Tagrisso for the treatment of unresectable,
Tagrisso Approved for Stage III Unresectable EGFR-Mutated NSCLC
FDA has approved Tagrisso for the treatment of adult patients with locally advanced, unresectable NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy.
AstraZeneca’s Tagrisso approved by FDA to treat EGFR-mutated lung cancer
Tagrisso (osimertinib) has been approved by the US Food and Drug Administration (FDA) to treat a new subset of lung cancer patients. The epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor has been specifically authorised to treat unresectable,
FDA Approves Tagrisso for Some With Advanced NSCLC
Tagrisso has been approved for some adults with locally advanced, unresectable stage 3 non-small cell lung cancer.
AstraZeneca: FDA Approves Tagrisso To Treat Unresectable Stage III Lung Cancer
British drug major AstraZeneca PLC (AZN, AZN.L) announced Thursday that its Tagrisso (osimertinib) has been approved in the US for
FDA approves new use for Tagrisso
The US Food and Drug Administration (FDA) has approved a new indication for AstraZeneca’s Tagrisso (osimertinib), which is already the UK pharma major’s best-selling drug with second-quarter 2024 revenues of $1.
FDA Approves Osimertinib in Stage III NSCLC
The approval means an additional indication for osimertinib (Tagrisso; AstraZeneca) for adult patients who have unresectable stage III non–small cell lung cancer (NSCLC) with EGFR mutation.
AstraZeneca gets FDA expanded approval for Tagrisso
AstraZeneca (NASDAQ:AZN) has received FDA approval for its drug Tagrisso for the treatment of patients with unresectable Stage 3 EGFR-mutant non-small cell lung cancer, or NSCLC. The agency approved Tagrisso,
AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication
The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, ...
Cure Today4h
Oncology Drugs Approved by the FDA in September 2024
Throughout September, the FDA approved drugs for the treatment of diseases including lung cancer, multiple myeloma, thyroid ...
Business Wire5d
TAGRISSO ® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
TAGRISSO is indicated for patients with exon 19 deletions or exon 21 (L858R) mutations, as detected by a FDA-approved test. The approval follows a Priority Review by the Food and Drug ...
Medscape4d
FDA Okays Osimertinib After CRT in Locally Advanced, Unresectable NSCLC
The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment ...